Work

Supplementary Figures 1 - 3 from Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Year: 2023

Type: supplementary-materials

Abstract: PDF file, 584K, Supplementary Figures: S1. MLN8237 dose-escalation schema for relative bioavailability sub-study; S2. Relative bioavailability study schema: MLN8237 ECT versus PIC formulation. S3. Scans showing durable partial response after treatment with MLN8237 in a 52-year-old patient with platinum- and radiation-refractory ovarian cancer.

DOI: 10.1158/1078-0432.22451294

Authors: E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. Burris, Jeffrey R. Infante

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361882991

Cites:

Cited by:

Related to: 10